Drugs / PGDM1400
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT03928821 | Jul 2019 → Mar 2021 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT03205917 | Oct 2017 → Apr 2020 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT04983030 | Apr 2022 → Feb 2026 | AIDS, acquired immunodeficiency | Boris Juelg, MD PhD | Completed | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03721510 Comparator | Dec 2018 → Oct 2021 | HIV infectious disease | International AIDS Vaccine Initiative | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PGDM1400 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03928821 ↗ |
| Modality | Monoclonal antibody | “PGDM1400, PGT121 and VRC07-523LS mAbs are recombinant human IgG1 monoclonal antibodies” NCT03205917 ↗ |
| Route | Intravenous | “PGDM1400/Placebo (3mg/kg IV)” NCT03205917 ↗ |